Human recombinant interleukin-2 augments in vitro blastogenesis of bovine and porcine lymphocytes.
The recent cloning of the human gene encoding interleukin 2 (IL-2) has provided the means for economical production of large quantities of the pure lymphokine for clinical studies. Human recombinant interleukin 2 (HrIL-2) has been reported to have in vitro and in vivo immunomodulating effects in the murine system, suggesting the cloned gene product has cross-species activity. Bovine and porcine peripheral blood lymphocytes were tested for responsiveness to HrIL-2 in a lymphocyte blastogenesis assay. Not only was the HrIL-2 highly stimulatory but it also reconstituted lymphocyte responsiveness to maximal values following incubation with suboptimal concentrations of mitogen plus exogenous lymphokine. These studies suggest that HrIL-2 has the potential of serving as an in vivo modulator of immunoresponsiveness in domestic species. The contribution to food animal medicine will be considerable if administration of the lymphokine results in augmentation of antigen-specific immune responses when applied as an adjuvant, non-specific booster of pre-existing immunity, or for therapy of immunosuppression.
D000818:Animals; D002417:Cattle; D007376:Interleukin-2 / Q000276:immunology*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology*; D013045:Species Specificity; D013552:Swine
D007376:Interleukin-2; D011994:Recombinant Proteins